|RxNews Recap for Wednesday 12-02-09|
|By Mary Davila|
|Wednesday, 02 December 2009 18:09|
Below is a list of the companies that made news in the healthcare sector on Wednesday, December 02, 2009.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
Genta Incorporated (OTCBB:GETA) announced that the Company will supply Ganite® (gallium nitrate injection) for a new clinical trial that will be initiated in patients with cystic fibrosis (CF) who may develop serious infections.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today provided updates on the regulatory review and approval, or commissioning, of Alexion’s Rhode Island manufacturing facility (ARIMF) in Smithfield, Rhode Island as a second source of supply for Soliris® (eculizumab).
Taro Pharmaceutical Industries Ltd. (“Taro,” the “Company,” Pink Sheets: TAROF) today provided information on its financial performance for the third quarter and nine months ended September 30, 2009.
Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.
Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, reported today that it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares.
Phosphagenics Limited (“Phosphagenics”) (ASX: POH; OTCQX: PPGNY) today announced the initiation of a Phase 1B clinical trial for its patented oxycodone/TPM (Targeted Penetration Matrix) transdermal patch systems.
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced availability of a webcast with results from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI).
CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.
Bristol-Myers Squibb Company (NYSE: BMY) today announced that more than 80 abstracts highlighting compounds from the company’s oncology portfolio will be presented at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held December 5-8 in New Orleans.
AmerisourceBergen (NYSE: ABC) today announced that it will hold its annual Investor Day in New York on Tuesday, December 15, 2009. The event will be webcast live beginning at 12:30 pm EST and ending at approximately 3:00 pm.
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled a webcast for 8:30 p.m. CT / 9:30 p.m. ET on Monday, December 7, 2009 to discuss clinical results for its lead JAK 1/JAK 2 inhibitor, INCB18424, which will be the subject of three oral presentations at the 51st American Hematology Annual Meeting in New Orleans.
PPD, Inc. (NASDAQ: PPDI) today announced it has launched a new global information technology infrastructure for analysis and reporting of clinical trial data.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission.
Hospira, Inc. (NYSE:HSP), a leading provider of clinical information and medication delivery technologies, announced today that it has acquired Salt Lake City-based TheraDoc, a clinical informatics company that develops hospital surveillance systems.